Cuideline and Consensus
Consensus on the whole-process management of in vitro diagnostic reagent clinical trial samples
Hubei Drug and Medical Device Clinical Evaluation Society, Drug Clinical Trial Committee of Chinese Pharmacological Society
Published 2022-10-19
Cite as Chin J Lab Med, 2022, 45(10): 1039-1044. DOI: 10.3760/cma.j.cn114452-20220119-00031
Abstract
In recent years, the National Medical Products Administration (NMPA) has formulated a series of relevant policies and guidelines for clinical trials of in vitro diagnostic reagents(IVD), which have put forward higher requirements for the scientificity and standardization of clinical trials of in vitro diagnostic reagents, which will help to promote standardized development of the IVD industry and enhance capabilities of conducting clinical trial. In order to further standardize the sample management of IVD clinical trial, the source, serial number, preservation, use, retention, destruction and other key links of the whole process of the samples used for testing, this consensus is jointly formulated in combination with the relevant guiding principles and the latest policy requirements, and the suggestions and opinions of experts in this field. This consensus is aimed to provide reference, guidance, and standard operational norms for the whole-process management of samples for IVD clinical trials.
Key words:
In vitro diagnostic reagents; Clinical trials; Samples; Whole process management
Contributor Information
Hubei Drug and Medical Device Clinical Evaluation Society
Drug Clinical Trial Committee of Chinese Pharmacological Society